Baptized by Covid-19 fire, Brii Bio reaps $320M Hong Kong IPO to carry on with pipeline for infectious diseases and beyond
Zhi Hong started Brii Bio three years ago with the clear vision that his trans-Pacific startup should have the best of both worlds — top-notch innovation from the US, vast patient pool and market in China — tethered by his years of experience working at GlaxoSmithKline’s infectious disease team.
In a sense, the strategy was exemplified (even if slightly reversed) as the biotech decided to join the hunt for a Covid-19 antibody early last year: Its drug, which was developed together with Chinese scientists based on monoclonal antibodies isolated from recovered patients in China, was selected by the NIH for large-scale platform trials in the US.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
